title: Overexpression of TFIIB-related factor 2 is significantly  correlated with tumor angiogenesis and poor survival in patients  with esophageal squamous cell cancer.
abstract: Studies have shown that genetic activation of TFIIB-related factor 2 (BRF2) represents a unique mechanism of tumorigenesis through the increase in Pol III-mediated transcription. Several studies have shown that BRF2 is overexpressed in several types of cancer and suggest the oncogenic role of BRF2. This study aimed to examine the expression of TFIIB-related factor 2 (BRF2) in patients with esophageal squamous cell cancer (ESCC) and explore the relationship of BRF2 expression with clinicopathologic factors, tumor angiogenesis and prognosis. We found that increased BRF2 protein expression was prevalent in esophageal squamous cell cancer and was significantly associated with deeper tumor invasion (P = 0.039) and microvessel density (P = 0.007). Additionally, expression of BRF2 was found to be an independent prognostic factor in ESCC patients. Furthermore, a significant correlation between high BRF2 expression and shorter overall survival time was found in different subgroups of ESCC patients stratified by the clinical stage, T classification and lymph node metastasis. High expression of BRF2 protein is closely associated with tumor progression and angiogenesis and poor survival of ESCC. BRF2 is a promising biomarker to identify individuals with poor prognostic potential and concludes the possibility of its use as a prognostic marker in patients with ESCC.
authors.affiliation: Department of Thoracic Surgery, Qilu Hospital, Shandong University, 44# Wenhua Xi Road, Jinan 250012, People's Republic of China. lumingqilu@126.com
authors.forename: Ming
authors.initials: M
authors.lastname: Lu
authors.forename: Hui
authors.initials: H
authors.lastname: Tian
authors.forename: Weiming
authors.initials: W
authors.lastname: Yue
authors.forename: Lin
authors.initials: L
authors.lastname: Li
authors.forename: Shuhai
authors.initials: S
authors.lastname: Li
authors.forename: Lei
authors.initials: L
authors.lastname: Qi
authors.forename: Wensi
authors.initials: W
authors.lastname: Hu
authors.forename: Cun
authors.initials: C
authors.lastname: Gao
authors.forename: Libo
authors.initials: L
authors.lastname: Si
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D004938:Esophageal Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000401:mortality; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D055806:Microvessels / Q000378:metabolism; D008875:Middle Aged; D018307:Neoplasms, Squamous Cell / Q000235:genetics / Q000378:metabolism* / Q000401:mortality; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000235:genetics* / Q000378:metabolism; D015996:Survival Rate / Q000639:trends; D035581:Transcription Factor TFIIB / Q000096:biosynthesis / Q000235:genetics; D035361:Transcription Factor TFIIIB / Q000096:biosynthesis / Q000235:genetics*
chemical_list: C416185:BRF2 protein, human; D014408:Biomarkers, Tumor; D035581:Transcription Factor TFIIB; D035361:Transcription Factor TFIIIB
references.citation: Nat Struct Mol Biol. 2006 Dec;13(12):1097-101
references.pmid: 17099701
references.citation: Ann Surg Oncol. 2009 Feb;16(2):506-14
references.pmid: 19050962
references.citation: Mol Cancer. 2011 Apr 25;10:47
references.pmid: 21518452
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Eur J Cancer. 2002 Aug;38(12):1564-79
references.pmid: 12142044
references.citation: Circ Res. 2007 Jul 6;101(1):59-68
references.pmid: 17540974
references.citation: Mol Cell. 2007 May 11;26(3):367-79
references.pmid: 17499043
references.citation: PLoS One. 2006 Dec 27;1:e134
references.pmid: 17205138
references.citation: Cancer. 2003 Apr 1;97(7):1616-23
references.pmid: 12655517
references.citation: Circ Res. 2007 Apr 27;100(8):1164-73
references.pmid: 17379831
references.citation: PLoS Med. 2010 Jul 27;7(7):e1000315
references.pmid: 20668658
references.citation: Blood. 2006 Nov 1;108(9):3068-71
references.pmid: 16849646
references.citation: PLoS One. 2012;7(10):e45622
references.pmid: 23056210
references.citation: Clin Cancer Res. 2005 Sep 1;11(17):6190-7
references.pmid: 16144920
references.citation: World J Surg. 2009 Sep;33(9):1876-81
references.pmid: 19575142
references.citation: Neoplasia. 2007 Feb;9(2):166-80
references.pmid: 17356713
references.citation: Mol Cell Biol. 1996 Dec;16(12):7084-8
references.pmid: 8943363
references.citation: J Mol Biol. 2001 Jun 29;310(1):1-26
references.pmid: 11419933
references.citation: Int J Biol Sci. 2007 May 01;3(5):292-302
references.pmid: 17505538
references.citation: J Clin Oncol. 2006 May 10;24(14):2137-50
references.pmid: 16682732
references.citation: Nucleic Acids Res. 2001 Jul 1;29(13):2675-90
references.pmid: 11433012
references.citation: J Mol Biol. 2008 May 2;378(3):481-91
references.pmid: 18377933
references.citation: Nat Rev Cancer. 2010 Feb;10(2):138-46
references.pmid: 20094048
references.citation: Biochem Biophys Res Commun. 2007 Sep 7;360(4):778-83
references.pmid: 17624304
references.citation: BMC Mol Biol. 2008 Aug 12;9:74
references.pmid: 18700021
references.citation: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references.pmid: 15761078
references.citation: Genes Dev. 2002 Oct 15;16(20):2593-620
references.pmid: 12381659